Mixed GHB Salts for Narcolepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GHB formulations, such as sodium oxybate (Xyrem®), pose challenges due to high sodium content, which is undesirable for patients with hypertension, heart disease, or at risk of stroke, and carry risks of abuse and misuse, leading to serious medical issues. Additionally, there is a lack of research on salts other than sodium oxybate and limited understanding of combining multiple salts for improved health benefits and reduced side effects.
Innovation Solution
Development of pharmaceutical compositions comprising a mixture of gamma-hydroxybutyrate (GHB) salts, including sodium, potassium, magnesium, and calcium salts, which are formulated to minimize sodium content, enhance solubility, stability, and purity, and provide effective and consistent dosing, while maintaining acceptable pharmacodynamic and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium oxybate (Xyrem®) is used for treating narcolepsy and fibromyalgia, then therapeutic effectiveness is achieved, but sodium intake increases significantly which is undesirable for patients with hypertension, heart disease, or renal disease
Solution Approach 1:
The patent changes the chemical composition parameters by replacing sodium cations with alternative cations (potassium, calcium, magnesium, or ammonium) in the gamma-hydroxybutyrate salt formulations, thereby reducing sodium content while maintaining therapeutic effectiveness for narcolepsy and fibromyalgia treatment
Solution Approach 2:
The patent employs composite salt formulations containing multiple cation types (e.g., combinations of potassium, calcium, magnesium, and/or ammonium with gamma-hydroxybutyrate) to achieve both therapeutic efficacy and reduced sodium intake, creating a composite material that addresses multiple requirements simultaneously
2Reliability
If high levels of sodium oxybate are used for chronic treatment, then treatment efficacy is maintained, but risks of abuse and misuse increase leading to serious medical problems including seizures, loss of consciousness, coma, and death
Solution Approach 1:
The patent modifies the chemical parameters by using alternative cations (potassium, calcium, magnesium, ammonium) instead of sodium in gamma-hydroxybutyrate formulations, which maintains the desired central nervous system effects for treating narcolepsy and fibromyalgia while reducing the abuse and misuse risks associated with high-dose sodium oxybate
3Reliability
If multiple GHB salts are combined in pharmaceutical compositions, then solubility and stability are enhanced, but formulation complexity increases
Solution Approach 1:
The patent creates composite salt formulations combining multiple cation types (potassium, calcium, magnesium, ammonium) with gamma-hydroxybutyrate in specific ratios, which enhances solubility and stability properties while the composite structure itself manages the complexity through defined compositional ranges
Data Source
AI summary
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.